Marcus Miethke

TL;DR: In this paper, the authors present a strategic blueprint to substantially improve our ability to discover and develop new antibiotics, and propose both short-term and long-term solutions to overcome the most urgent limitations in the various sectors of research and funding.

TL;DR: Genetic and phenotypic experiments concordantly show that aurantimycin A is a substrate of the LieAB transporter and thus, lftRS and lieAB represent the first known genetic module conferring and regulating auranticcin A resistance.

TL;DR: The semisynthetic modification of amidochelocardin, an atypical tetracycline obtained via genetic engineering of the chelocardin producer strain, is reported by the application of methylation, acylation, electrophilic substitution, and oxidative C-C coupling reactions.

TL;DR: This study shows that both chelocardin and amidochelocardin possess resistance-breaking properties enabling the escape from most common tetracycline resistance mechanisms, and shows that these compounds are potent candidates for treatment of urinary tract infections due to their in vitro activity against a large panel of multidrug-resistant uropathogenic clinical isolates.